Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonatan Salzer

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 4, 2013
Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samplesJonatan Salzer, Maria Nyström, Göran Hallmans, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 22, 2012
Smoking as a risk factor for multiple sclerosisJonatan Salzer, Göran Hallmans, Maria Nyström, et al.
Journal of Neurology|November 26, 2015
Rituximab in paediatric onset multiple sclerosis: a case seriesJonatan Salzer, Jan Lycke, Ronny Wickström, et al.
JAMA Neurology|January 9, 2018
Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple SclerosisMathias Granqvist, Malin Boremalm, Amyar Poorghobad, et al.
Annals of Neurology|June 11, 2024
Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control StudyViktor Grut, Martin Biström, Jonatan Salzer, et al.
Annals of Neurology|April 3, 2016
Rituximab versus fingolimod after natalizumab in multiple sclerosis patientsPeter Alping, Thomas Frisell, Lenka Novakova, et al.
European Journal of Neurology|May 18, 2022
Free vitamin D<sub>3</sub> index and vitamin D-binding protein in multiple sclerosis: A presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|November 28, 2022
Systemic inflammation and risk of multiple sclerosis - A presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
European Journal of Neurology|May 25, 2024
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort studySusanna Hallberg, Björn Evertsson, Ellen Lillvall, et al.
Plos One|June 12, 2026
Internet-based vestibular rehabilitation versus written instructions after acute vertigo: A randomised controlled trialSolmaz Surano, Ellen Lindell, Jan Mathé, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 4, 2013
Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samplesJonatan Salzer, Maria Nyström, Göran Hallmans, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 22, 2012
Smoking as a risk factor for multiple sclerosisJonatan Salzer, Göran Hallmans, Maria Nyström, et al.
Journal of Neurology|November 26, 2015
Rituximab in paediatric onset multiple sclerosis: a case seriesJonatan Salzer, Jan Lycke, Ronny Wickström, et al.
JAMA Neurology|January 9, 2018
Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple SclerosisMathias Granqvist, Malin Boremalm, Amyar Poorghobad, et al.
Annals of Neurology|June 11, 2024
Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control StudyViktor Grut, Martin Biström, Jonatan Salzer, et al.
Annals of Neurology|April 3, 2016
Rituximab versus fingolimod after natalizumab in multiple sclerosis patientsPeter Alping, Thomas Frisell, Lenka Novakova, et al.
European Journal of Neurology|May 18, 2022
Free vitamin D<sub>3</sub> index and vitamin D-binding protein in multiple sclerosis: A presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|November 28, 2022
Systemic inflammation and risk of multiple sclerosis - A presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
European Journal of Neurology|May 25, 2024
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort studySusanna Hallberg, Björn Evertsson, Ellen Lillvall, et al.
Plos One|June 12, 2026
Internet-based vestibular rehabilitation versus written instructions after acute vertigo: A randomised controlled trialSolmaz Surano, Ellen Lindell, Jan Mathé, et al.
Pageof 5